Loading...
XBRUMITRA
Market cap15mUSD
Apr 26, Last price  
0.22EUR
Name

Mithra Pharmaceuticals SA

Chart & Performance

D1W1MN
XBRU:MITRA chart
P/E
—
P/S
0.36
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.58%
Rev. gr., 5y
-7.05%
Revenues
40m
-40.06%
14,752,00017,677,00019,038,00020,435,00022,468,00032,042,00057,876,00096,520,0009,030,00022,668,00066,997,00040,155,000
Net income
-174m
L+191.01%
-627,000-1,528,000-2,955,000-9,821,000-35,087,000-38,360,000-27,606,000-26,564,000-92,086,000-116,875,000-59,620,000-173,502,000
CFO
-2m
L-96.72%
901,000516,000-673,000-18,064,000-23,412,000-31,061,0003,542,000-50,147,000-83,528,000-86,152,000-66,681,000-2,184,000
Earnings
May 30, 2025

Profile

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
URL
https://www.mithra.com/
IPO date
Jun 30, 2015
Employees
229
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
40,155
-40.06%
66,997
195.56%
22,668
151.03%
Cost of revenue
121,690
112,379
125,779
Unusual Expense (Income)
NOPBT
(81,535)
(45,382)
(103,111)
NOPBT Margin
Operating Taxes
11,707
46,059
(9,462)
Tax Rate
NOPAT
(93,242)
(91,441)
(93,649)
Net income
(173,502)
191.01%
(59,620)
-48.99%
(116,875)
26.92%
Dividends
Dividend yield
Proceeds from repurchase of equity
50,041
9,213
BB yield
-29.96%
-1.06%
Debt
Debt current
33,153
52,411
53,128
Long-term debt
210,792
176,015
167,590
Deferred revenue
8,127
12,769
Other long-term liabilities
106,659
127,987
148,189
Net debt
218,950
175,818
155,859
Cash flow
Cash from operating activities
(2,184)
(66,681)
(86,152)
CAPEX
(25,658)
(21,182)
Cash from investing activities
3,452
(25,490)
(54,682)
Cash from financing activities
(20,538)
87,731
35,010
FCF
(12,521)
(105,722)
(77,853)
Balance
Cash
8,980
28,285
32,872
Long term investments
16,015
24,323
31,987
Excess cash
22,987
49,258
63,726
Stockholders' equity
(528,114)
(374,960)
(306,929)
Invested Capital
743,832
734,934
680,092
ROIC
ROCE
EV
Common stock shares outstanding
69,124
49,059
43,430
Price
1.25
-63.29%
3.41
-82.96%
19.98
1.42%
Market cap
86,405
-48.27%
167,047
-80.75%
867,728
7.46%
EV
305,355
342,865
1,023,587
EBITDA
(69,321)
(33,442)
(92,685)
EV/EBITDA
Interest
22,899
17,031
12,115
Interest/NOPBT